retatrutide clinical trial phase Retatrutide: FDA approval time, results & weight loss VisualAbstract: Retatrutide reduces body weight

According to FDA guidance, GLP-1 medications are not recommended for people who have: Pregnancy, because safety data are limited and pregnancy requires appropriate weight gain and nutrient storage A prior history of pancreatitis, due to a risk of triggering inflammation of the pancreas A history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), a rare genetic condition linked to thyroid cancer in animal studies A clinician will review your medical history carefully to determine whether these medications are appropriate for you

PeterMD mentions a provider check-in at the three-month mark

The positive reviews that do exist praise delivery speed and medication effectiveness, but they are outweighed by the critical feedback

Safety note The most notable is the heart rate increase observed in the retatrutide Phase 2 trial

Our Role in Metabolic Research Support Retatrutide is being investigated for its interaction with GLP-1, GIP, and glucagon receptors